A Multi-Arm, Phase 3, Randomized, Placebo Controlled, Double Blind Cli
Research payments
$2,034,702
Through program year 2022, $2,034,702 in research payments was reported against A Multi-Arm, Phase 3, Randomized, Placebo Controlled, Double Blind Cli, across 722 payments, paid by ViiV Healthcare Company.
- Paid by
- ViiV Healthcare Company
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $106,400 | 26 |
| 2021 | Research | $431,832 | 207 |
| 2020 | Research | $769,865 | 240 |
| 2019 | Research | $726,605 | 249 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Melanie Thompson Atlanta, GA Named on 49 payments
- Richard Loftus Rancho Mirage, CA Named on 31 payments
- Robert Grossberg Bronx, NY Named on 28 payments
- Javier Morales Santurce, PR Named on 25 payments
- Princy Kumar Washington, DC Named on 21 payments
- Joseph McGowan Manhasset, NY Named on 21 payments
- Debbie Hagins Savannah, GA Named on 20 payments
- Anthony Mills Los Angeles, CA Named on 20 payments
- Mamta Jain Dallas, TX Named on 19 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.